ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.175,21
1,01%
S&P 500
5.180,74
1,03%
Dow Jones
38.852,27
0,46%
Euro vs US Dollar
1,07674
0,00%
Bitcoin
63.534,06
0,58%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Neoleukin Therapeutics Inc (NLTX)

  7. Neoleukin Therapeutics Inc (NLTX) News

NLTX Neoleukin Therapeutics Inc

3,49
0,00 (0,00%)
06 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Neoleukin Therapeutics Inc NLTX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,00 0,00% 3,49 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
3,49 3,49
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
26.4.202420:34EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
26.4.202420:33EDGAR2Form ARS - Annual Report to Security Holders
26.4.202420:33EDGAR2Form DEF 14A - Other definitive proxy statements
22.4.202422:44EDGAR2Form 8-K - Current report
02.4.202421:43EDGAR2Form 8-K - Current report
18.3.202421:10EDGAR2Form 8-K - Current report
18.3.202421:04EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15.3.202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.3.202401:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.3.202401:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202422:29EDGAR2Form 144 - Report of proposed sale of securities
05.3.202400:20EDGAR2Form 144 - Report of proposed sale of securities
04.3.202413:30EDGAR2Form 8-K - Current report
21.2.202422:07EDGAR2Form 8-K - Current report
20.2.202422:16EDGAR2Form S-8 - Securities to be offered to employees in employee..
15.2.202400:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14.2.202422:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202422:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14.2.202421:08EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14.2.202415:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06.2.202422:18EDGAR2Form 144 - Report of proposed sale of securities
19.1.202401:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.1.202400:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.1.202400:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.1.202400:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.1.202400:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.1.202400:45EDGAR2Form 3 - Initial statement of beneficial ownership of..
05.1.202413:11EDGAR2Form 8-K - Current report
27.12.202300:16EDGAR2Form 3 - Initial statement of beneficial ownership of..
27.12.202300:12EDGAR2Form 3 - Initial statement of beneficial ownership of..
27.12.202300:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
27.12.202300:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
27.12.202300:04EDGAR2Form 3 - Initial statement of beneficial ownership of..
22.12.202322:15EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
21.12.202322:05EDGAR2Form SC 13D - General statement of acquisition of beneficial..
19.12.202313:31EDGAR2Form 8-K - Current report
15.12.202301:00GLOBENeoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
06.12.202322:24EDGAR2Form 425 - Prospectuses and communications, business..
06.12.202322:21EDGAR2Form 8-K - Current report
04.12.202323:14EDGAR2Form 425 - Prospectuses and communications, business..
04.12.202323:10EDGAR2Form 8-K - Current report
30.11.202322:06EDGAR2Form 425 - Prospectuses and communications, business..
08.11.202320:34EDGAR2Form S-4/A - Registration of securities, business..
18.10.202322:09EDGAR2Form S-4/A - Registration of securities, business..
05.10.202318:50EDGAR2Form 425 - Prospectuses and communications, business..
28.9.202322:28EDGAR2Form S-4/A - Registration of securities, business..
22.9.202314:03EDGAR2Form 8-K - Current report
22.9.202314:00GLOBENeoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
14.8.202322:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10.8.202322:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Kürzlich von Ihnen besucht

NASDAQ
NLTX
Neoleukin Therapeutics
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten